Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a a prospective, single-arm phase II clinical trial. The purpose of this study is to
evaluate the efficacy and adverse effect of PD-1 antibody with chemotherapy in high-risk
recurrent nasopharyngeal carcinoma.